Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric spectrum of HIV disease, 1989-2004

Pediatrics

Volumn 119, Issue 4, 2007, Pages

  Schulte, Joann ^a,b   Dominguez, Ken ^a   Sukalac, Thomas ^a   Bohannon, Beverly ^a   Fowler, Mary Glenn ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

HIV infected women; Low birth weight; Preterm birth

Indexed keywords

ANTIRETROVIRUS AGENT; ILLICIT DRUG; PROTEINASE INHIBITOR; ZIDOVUDINE;

AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFANT DISEASE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; NEWBORN PERIOD; PREGNANCY COMPLICATION; PREMATURE LABOR; PREMATURITY; PRENATAL CARE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; TREND STUDY;

ANALYSIS OF VARIANCE; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COHORT STUDIES; CONFIDENCE INTERVALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; LOGISTIC MODELS; MALE; MATERNAL WELFARE; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; REGISTRIES; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 34147120217     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-1123     Document Type: Article

References (43)

1. McCormick MC. The contribution of low birth weight to into mortality and childhood morbidity. N Engl J Med. 1985;312:82-90
2. Hamilton BE, Martin JA, Ventura SJ, Sutton PD, Menacker F. Births: preliminary data for 2004. Natl Vital Stat Rep. 2005;54:1-18.
3. Branum AM, Schoendorf KC. Changing patterns of low birthweight and preterm birth in the United States, 1981-98. Pediatr Perinat Epidemiol. 2002;16:8-15
4. Alexander GR, Kogan M, Bader D, Carlo W, Allen M, Mor J. US birthweight/gestational age-specific neonatal mortality: 1995-1997 rates for whites, Hispanics, and blacks. Pediatrics. 2003;111(1). Available at: www.pediatrics.org/cgi/content/full/111/1/e61
5. Desenclos JC, Scaggs M, Wroten JE. Characteristics of mothers of live infants of congenital syphilis in Florida, 1987-1989. Am J Epidemiol. 1992;136:657-661
6. Lambert JS, Watts DH, Mofenson L, et al. Risk factors for preterm birth, low birthweight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. AIDS. 2000;14:1389-1399
7. Simonds RJ, Steketee R, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS. 1998;12:301-308
8. Stratton P, Tuomala RE, Abboud R, et al. Obstetric and newborn outcomes in a cohort of HIV-infected infected pregnant women: a report of the Women and Infants Transmission Study. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:179-186
9. Turner BJ, McKee LJ, Silverman NS, Hauck WW, Fanning TR, Markson LE. Prenatal care and birth outcomes of a cohort of HIV-infected women. J Acquir Immun Defic Syndr Hum Retrovirol. 1996;12:259-267
10. Goldstein PJ, Smith R, Stevens M, Sever JL. Association between HIV in pregnancy and antiretroviral therapy, including PIs, and low birthweight infants. Infect Dis Obstet Gynecol. 2000;8:94-98
11. Nair P, Alger L, Hines S, Seiden S, Hebel R, Johnson JP. Maternal and neonatal characteristics associated with HIV infection in the infants of seropositive women. J Acquir Immune Defic Syndr. 1993;6:298-302
12. Turner BJ, Newschaffer CJ, Cocroft J, Fanning TR, Marcus S, Hauck WW. Improved birth outcomes among HIV-infected infected women with enhanced Medicaid prenatal care. Am J Public Health. 2000;90:85-91
13. Martin R, Boyer P, Hammill H, et al. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. J Pediatr. 1997;131:851-856
14. Newschaffer CJ, Cocraft J, Hauck WW, Fanning T, Turner BJ. Improved birth outcomes associated with enhanced Medicaid prenatal care in drug-using women infected with human immunodeficiency virus. Obstet Gynecol. 1998;91:885-891
15. Landesman SH, Kalish LA, Burns DN, et al. Obstetric factors in the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med. 1996;334:1617-1623
16. European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14:2913-2920
17. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346:1863-1870
18. Covington D, Garcia P, Ross B, Chavers S, Tilson H. Association between antiretroviral therapy during pregnancy and prematurity/low birth weight [abstract 97]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA
19. Szyld E, Gonin R, Warley E, et al. Receipt of PI-containing HAART during pregnancy and adverse pregnancy outcomes (low birth weight, preterm birth) among HIV-1-infected women in Latin America and the Caribbean: the NICHD International Site Development Initiative Perinatal Study [abstract 608]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA
20. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18:2337-2339
21. Markson LE, Turner BJ, Houchens R, Silverman NS, Cosler L, Takyi BK. Association of maternal HIV infection with low birthweight. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;18:227-234
22. Morris AB, Dobles AR, Cu-Uvin S, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr. 2005;40:30-33
23. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449-473
24. Cotter AM, Garcia AG, Duthely L, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight or stillbirth? J Infect Dis. 2006;193:1195-1201
25. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternalinfant transmission of HIV-1. JAMA. 2001;285:2083-2093
26. Lorenzi P, Spicher VM, Laubereau B, et al. Antiviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative and Pregnancy Study, and the Swiss Neonatal HIV study. AIDS. 1998;12:F241-F247
27. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV infected women. J Acquir Immune Defic Syndr. 2003;32:380-387
28. Blair JM, Hanson DL, Jones JL, et al. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol. 2004;103:663-668
29. Mofenson LM, Centers for Disease Control and Prevention, US Public Health Service Task Force. US Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep. 2002;51:1-38
30. The European Mode of Delivery Collaboration. Elective Caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet. 1999;353:1035-1039
31. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. N Engl J Med. 1999;340:977-987
32. Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease project. Pediatrics. 1996;97:710-716
33. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-15
34. Dominguez KL, Lindgren ML, d'Alamada PJ, et al. Increasing trend of cesarean deliveries in HIV-infected women in the United States from 1994 to 2000. J Acquir Immune Defic Syndr. 2003;33:232-238
35. SAS Institute. Principles of Regression Analysis. Cary, NC: SAS Institute; 1996
36. Lindgren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA. 1999;282:531-538
37. Connor EM, Sperling RS, Gelber RE, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180
38. Centers for Disease Control and Prevention. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Recomm Rep. 1995;44(RR-7):1-15
39. Lansky A, Jones JL, Frey RL, Lindgren ML. Trends in HIV testing among pregnant women: United States, 1994-1999. Am J Public Health. 2001;90:1291-1293
40. Shiono PH, Rauh VA, Park M, Lederman SA, Zuskar D. Ethnic differences in birth weight: the role of lifestyle and other factors. Am J Public Health. 1997;87:787-793
41. Hessol NA, Fuentes-Afflick E, Bacchetti P. Risk of low birthweight infants among black and white parents. Obstet Gynecol. 1998;92:814-822
42. Day NL, Cottreau CM, Richardson GA. The epidemiology of alcohol, marijuana, and cocaine use in the women of childbearing age and pregnant women. Clin Obstet Gynecol. 1993;36:232-245
43. Ickovics JR, Wilson TE, Ethier KA, Koenig LJ, Walter EB. Infant birthweight among women who were at high risk for HIV infection: the impact of clinical, behavioral, psychosocial and demographic factors. Health Psychol. 2000;19:515-523